Apellis Pharmaceuticals Inc share price logo

Apellis Pharmaceuticals Inc

NASDAQ: APLS

Mid Cap

$41.05

-0.02

(-0.04%)

Live

as on

Apellis Pharmaceuticals Inc Stock Performance

as on May 14, 2026 at 4:08 am IST

  • Day's Low

    $41.03
    $41.05
    downward going graph

    0.05%

    Downside

  • 52 Week's Low

    52 Week's High

    $16.10
    $41.14
    downward going graph

    60.78%

    Downside

    0.22%

    Upside

    downward going graph

Apellis Pharmaceuticals Inc share price movements today

Previous Close
$41.06
Open
$41.05
Volume
5.4M
Day's Low - High
$41.03 - $41.05
52 Week Low - High
$16.10 - $41.14

Apellis Pharmaceuticals Inc Historical Returns

1 Month Return
+ 0.54 %
3 Month Return
+ 89.22 %
1 Year Return
+ 137.62 %
3 Year Return
-53.32 %
5 Year Return
-10.04 %

Apellis Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Apellis Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.3B

EPS (TTM)

-1.1343

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

38.34

Industry PE ratio

-10.504558823529411

PEG Ratio

0

EBITDA

166.6M

Revenue (TTM)

1.1B

Profit Margin

12.06%

Return On Equity TTM

46.02%

Apellis Pharmaceuticals Inc Stock Valuation

Track how Apellis Pharmaceuticals Inc P/E has moved over time to understand its valuation trends.

Apellis Pharmaceuticals Inc in the last 5 years

  • Overview

  • Trends

Lowest (-20.71x)

December 31, 2024

Industry (-10.50x)

May 13, 2026

Today (38.34x)

May 13, 2026

Highest (180.48x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 38.34x

Apellis Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Apellis Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Apellis Pharmaceuticals Inc image
Apellis Pharmaceuticals Inc
BUY$5.3B-10.04%38.3412.06%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$38.0B119.7%71.3912.55%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.7BNA71.448.94%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.4B109.14%25.8435.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.7B39.88%17.3929.65%

Stock Returns calculator for Apellis Pharmaceuticals Inc Stock including INR - Dollar returns

The Apellis Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Apellis Pharmaceuticals Inc investment value today

Current value as on today

₹2,66,615

Returns

₹1,66,615

(+166.62%)

Returns from Apellis Pharmaceuticals Inc Stock

₹1,37,558 (+137.56%)

Dollar Impact

₹29,057 (+29.06%)

Analyst Recommendation on Apellis Pharmaceuticals Inc Stock

Based on 23 analysts

BUY

82.61%

Buy

17.39%

Hold

0.00%

Sell

Based on 23 analysts, 82.61% of analysts recommend a 'BUY' rating for Apellis Pharmaceuticals Inc. Average target price of $40.93

Apellis Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Apellis Pharmaceuticals Inc.

What analysts predicted

-0.29%DOWNSIDE

Target Price

$40.93

Current Price

$41.05

Analyzed by

23 Analysts

Target

$40.93

Apellis Pharmaceuticals Inc target price $40.93, a slight downside of -0.29% compared to current price of $41.05. According to 23 analysts rating.

Indian Investors' Interest in Apellis Pharmaceuticals Inc Stock

Search interest for Apellis Pharmaceuticals Inc Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-50% versus previous 30 day period

Apellis Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
146
172
199
196
212
166
178
458
199
268
Gross Profit
126
151
176
163
171
132
164
434
170
227
Operating Income
-84
-62
-29
-47
-26
-83
-33
223
-51
26
EBITDA
-79
-58
-27
-43
-24
-80
-30
227
-47
26
Interest Expense
7
6
9
12
11
11
11
11
10
10
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-87
-66
-37
-56
-36
-91
-41
216
-58
19
Income Tax Expense
1
0
0
0
0
0
0
0
0
0
Net Income
-88
-66
-37
-57
-36
-92
-42
215
-58
18
Net Profit Margin
-60.51%
-38.55%
-18.86%
-29.19%
-17.11%
-55.29%
-23.61%
47.04%
-29.49%
6.95%

Apellis Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
250
66
75
396
781
1,003
Gross Profit
-
-50
-127
0
225
61
69
338
663
901
Operating Income
-27
-50
-127
-288
-213
-536
-594
-517
-164
55
EBITDA
-27
-50
-125
-298
-312
-731
-617
-495
-154
69
Interest Expense
-
0
2
5
29
13
32
29
40
44
Depreciation
-
0
-
0
0
1
1
1
1
1
Income Before Tax
-27
-51
-127
-304
-343
-746
-651
-526
-196
24
Income Tax Expense
-27
0
0
5
1
0
0
2
1
1
Net Income
-27
-51
-127
-304
-344
-746
-652
-528
-197
22
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-137.59%
-1121.27%
-864.70%
-133.29%
-25.32%
2.23%

Apellis Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-66
-37
-57
-36
-92
-42
215
-81
18
Operating Cash Flow
-132
-8
34
19
-53
4
108
-14
-60
Investing Cash Flow
0
0
-
0
0
0
0
0
-
Financing Cash Flow
108
42
2
-4
0
6
0
1
0
Change in Cash
-25
34
36
14
-52
11
109
-12
-61

Apellis Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-51
-127
-304
-344
-746
-652
-528
-197
22
Operating Cash Flow
-46
-131
-211
-160
-563
-513
-594
-87
45
Investing Cash Flow
-1
-1
-1
-316
247
59
0
0
0
Financing Cash Flow
197
131
388
692
392
365
394
149
8
Change in Cash
150
0
175
215
74
-88
-200
60
55

Global Institutional Holdings in Apellis Pharmaceuticals Inc

Funds
Holdings
Geode Capital Management, LLC
1.58%
Dimensional Fund Advisors, Inc.
1.05%
NORGES BANK
0.94%
venBio Select Advisor LLC
9.55%
Vanguard Group Inc
8.34%
See all

Apellis Pharmaceuticals Inc News & Key Events

  • img

    Today's Timeline - 31 March

    Tue, 04:53 PM

    -

    Apellis shareholders to receive $41 per share in cash, a 140% premium, plus contingent payments based on sales milestones.

Insights on Apellis Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -58.95M → 18.65M (in $), with an average increase of 416.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, APLS stock has moved up by 89.2%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 199.91M → 268.29M (in $), with an average increase of 25.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, APLS has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 32.2% return, outperforming this stock by 85.5%

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
OrganisationApellis Pharmaceuticals Inc
Headquarters100 Fifth Avenue, Waltham, MA, United States, 02451
IndustryBiotechnology
CEODr. Cedric Francois M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Apellis Pharmaceuticals Inc

Name

Title

Mr. Alec Machiels J.D., MBA

Co-Founder & Director

Mr. Timothy E. Sullivan

CFO & Treasurer

Mr. David O. Watson Esq., J.D.

General Counsel & Secretary

Dr. Pascal Deschatelets Ph.D.

Co-Founder & Chief Scientific Officer

Mr. James G. Chopas CPA

VP, Corporate Controller & Chief Accounting Officer

Ms. Eva Stroynowski

Head of Investor Relations

Prof. Peter Hillmen M.D., Ph.D.

Head of Hematology Engagement & Member of PNH Scientific Advisory Board

Dr. Cedric Francois M.D., Ph.D.

Co-Founder, President, CEO & Director

Ms. Kelley Boucher

Chief People Officer

Dr. Caroline R. Baumal M.D.

Chief Medical Officer

FAQs

What is Apellis Pharmaceuticals Inc share price today?

Apellis Pharmaceuticals Inc share price today is $41.05 as on . Apellis Pharmaceuticals Inc share today touched a day high of $41.05 and a low of $41.03.

What is the 52 week high and 52 week low for Apellis Pharmaceuticals Inc share?

Apellis Pharmaceuticals Inc share touched a 52 week high of $41.14 on and a 52 week low of $16.1 on . Apellis Pharmaceuticals Inc stock price today i.e. is trending at $41.05,which is 0.22% down from its 52 week high and 154.97% up from its 52 week low.

What is Apellis Pharmaceuticals Inc's market capitalisation today?

Apellis Pharmaceuticals Inc market capitalisation is $0.01T as on .

How to invest in Apellis Pharmaceuticals Inc Stock (APLS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Apellis Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Apellis Pharmaceuticals Inc Shares that will get you 0.0365 shares as per Apellis Pharmaceuticals Inc share price of $41.05 per share as on May 13, 2026 at 10:38 pm IST.

What is the minimum amount required to buy Apellis Pharmaceuticals Inc Stock (APLS) from India?

Indian investors can start investing in Apellis Pharmaceuticals Inc (APLS) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Apellis Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Apellis Pharmaceuticals Inc share’s latest price of $41.05 as on May 13, 2026 at 10:38 pm IST, you will get 0.2436 shares of Apellis Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Apellis Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Apellis Pharmaceuticals Inc stock has given -10.04% share price returns and 29.72% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?